This is a patent with priority in 1999 describing the use of genetically modified Sertoli cells for immune protection of implanted cells AND the use of the Sertoli cells themselves as the vector...genetic engineer with any gene is covered.
This patent is part of the Canadian company Sernova's (CDNX:SVA.V) potent intellectual property...
This patent covers the use of mesenchymal stem cells to generate T suppressor cells in general. Specifically it mentions that CD8 positive T cells can be turned into suppressor cells by contact with mesenchymal stem cells. Usually, T suppressor cells are called T regulatory cells and this refers to CD4+ CD25Inventors: McIntosh, Kevin (Ellicott City, MD); Klyushnenkova, Elena (Baltimore, MD)
This patent discloses frequencies and methods of culturing stem cells in order to generate a source of bioartificial cartilage.
Repair of articular cartilage is a substantial problem. The patent is useful for entities interested in providing a solution to this problem through the administration of cellular therapy containing adipose-derived stem cells in a biocompatible matrix or delivery system. The patent specifically has 4 independent claims. The first claim covers a composition of matter that is useful for...
This patent teaches ways to make artificial cartilage patches using adipose stem cells as starting material. These patches may be useful for people having injuries in which cartilage is damaged. The patent has 1 independent claim which essentially covers producing such an artifical patch through taking out adipose stem cells, culturing the cells to become chondrocytes, allowing the...
This appears to be a very important patent in that it teaches the use of adipose stem cells for generating chondrocytes and using the chondrocytes to heal cartilage. This patent should be compared to ones by Osiris that use adipose derived mesenchymal stem cells for cartilage repair, as well as by Cytori which uses adipose derived stem cells for a variety of indications.
This patent teaches how to generate cartilage and chondrocytes from stromal cells that are derived from adipose tissues. Another company working heavily in this area is Cytori, formerly called Macropore.
This patent teaches that CXC chemokines are potent stimulators of hepatic stem cells and hepatic regeneration. Chemokines covered include MIP-2, ENA-78 and IL-8.
This is a composition patent covering myocardial and fibroblast cell preparations that are useful for administration in the post-infarct myocardium. This approach is interesting and a similar approach seems to have been used clinically by the company Bioheart.
This patent provides a medical device that detects ischemia based on electrical conductivity and other parameters. This invention is useful in combination with stem cell therapy so as to enable the administrator of stem cell angiogenic therapy to decide when and where therapy is needed.